Free Trial
NASDAQ:PHXM

PHAXIAM Therapeutics (PHXM) Stock Price, News & Analysis

PHAXIAM Therapeutics logo
$3.10 0.00 (0.00%)
As of 04/25/2025

About PHAXIAM Therapeutics Stock (NASDAQ:PHXM)

Key Stats

Today's Range
$3.10
$3.10
50-Day Range
$3.10
$3.10
52-Week Range
$2.50
$13.00
Volume
N/A
Average Volume
2,472 shs
Market Capitalization
$10.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Receive PHXM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAXIAM Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PHXM Stock News Headlines

PHAXIAM Therapeutics: Update on the Receivership Procedure
Phaxiam Therapeutics S.A.
Trump purposefully forcing markets to crash…
Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you ready for it?
See More Headlines

PHXM Stock Analysis - Frequently Asked Questions

PHAXIAM Therapeutics' stock was trading at $3.10 at the beginning of 2025. Since then, PHXM stock has increased by 0.0% and is now trading at $3.10.
View the best growth stocks for 2025 here
.

Shares of PHAXIAM Therapeutics reverse split on Wednesday, September 20th 2023. The 1-10 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of PHXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PHAXIAM Therapeutics investors own include Salesforce (CRM), AbbVie (ABBV), Bank of America (BAC), Chevron (CVX), Merck & Co., Inc. (MRK), The PNC Financial Services Group (PNC) and AGCO (AGCO).

Company Calendar

Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PHXM
Employees
49
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$32.66 million
Price / Cash Flow
N/A
Book Value
$7.98 per share
Price / Book
0.39

Miscellaneous

Free Float
3,346,000
Market Cap
$10.58 million
Optionable
No Data
Beta
2.35
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:PHXM) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners